Until recently, tamoxifen, a nonsteroidal antiestrogen, was the mainstay of endocrine
treatment of breast cancer. However, new aromatase inhibitors that are many times more …

Azole compounds play a key role as antifungals in agriculture and in human mycoses and
as non-steroidal antiestrogens in the treatment of estrogen-responsive breast tumors in …

Background: Most recurrences in women with breast cancer receiving 5 years of adjuvant
tamoxifen occur after 5 years. The MA. 17 trial, which was designed to determine whether …

Endocrine therapy with tamoxifen has been the mainstay of treatment for hormone-sensitive
breast cancer for more than 20 years. An alternative strategy of oestrogen deprivation in …

Abstract Development of breast cancer involves genetic factors as well as lifetime exposure
to estrogen. The precise molecular mechanisms whereby estrogens influence breast tumor …

Objective: To evaluate the ovarian follicular dynamics of cycle modification with the
aromatase inhibitor letrozole compared with clomiphene citrate in normal ovulatory women …

Recent clinical trials indicate that the third-generation aromatase inhibitors may be more
effective than tamoxifen as first line endocrine therapy in ER+ metastatic breast cancer in …

BACKGROUND The available data on effectiveness of aromatase inhibitors in treating pain
symptoms related to endometriosis is limited. We compared the efficacy and tolerability of …

Breast cancer is associated with endogenous hormone levels, but the exact relation and
underlying mechanisms remain unclear. Data from several retent epidemiologic studies …

Aromatase is the rate limiting enzyme that catalyzes the conversion of androgens to
estrogens. Blockade of this step allows treatment of diseases that are dependent upon …